The Drugs Controller General of India (DCGI) has granted emergency use authorisation for a new drug, 2-deoxy-D-glucose (2-DG), as adjunct therapy that can help lower supplemental oxygen dependence in moderate to severe Covid-19 patients.
Pfizer Canada and BioNTech have received Interim Order authorisation from Health Canada for the use of their Covid-19 vaccine in adolescents aged 12 to 15 years.
Johnson & Johnson (J&J) will resume Covid-19 vaccine roll-out in Europe following the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC), which confirmed the overall benefit-risk profile being positive.
The US Food and Drug Administration (FDA) has approved Investigational New Drug (IND) application submitted by Airway Therapeutics to develop AT-100 (rhSP-D) for treating patients with Covid-19.
Biotechnology company Anixa Biosciences, partnered by IT and pharma solutions company OntoChem, has announced that it will enter the next stage of development of its potential anti-viral therapy for Covid-19.
An international team led by researchers at the US National Institutes of Health (NIH) and the University of North Carolina at Chapel Hill have found that SARS-CoV-2 virus that causes Covid-19, infects cells in the mouth.
A branch of the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID) has granted $2.5m to 12 institutes across the world for bacteriophage therapy research.
Biopharmaceutical company Ocugen has announced that its co-development partner, Bharat Biotech, announced the results of the first interim analysis of its Phase 3 study of COVAXIN, which is a whole virion inactivated Covid vaccine candidate.
Janssen-Cilag International, a subsidiary of Johnson & Johnson has submitted a conditional marketing authorisation application (cMAA) to the European Medicines Agency (EMA) for its investigational single-dose Janssen COVID-19 vaccine candidate.
The University of Oxford, along with three partner sites in the UK, has commenced the first trial to evaluate the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.